Health and Development Novartis Symposium 4/14/01 Access to Medicine – The Role of Patent Rules Sophia Tickell- Oxfam GB. Trade Talks at Doha. Test of legitimacy of WTO & multilateral trading system. Patents/Medicines by far the biggest single issue. Outcome: Declaration.
“We Agree That the TRIPS Agreement Does Not and Should Not Prevent Members From Taking Measures to Protect Public Health”
Poor people buy medicines & struggle to do so in LDCs and DCs
Luweero, Uganda – ¾ poor families sell food crops to buy medicines
Colombia – 1 in 5 on/below poverty line – medicines = greatest household health expenditure.
Poor governments do too
61 DCs average medicine spend = S$102. Why does it matter? – Poor people can barely afford medicines
Local generics industry allows governments to negotiate over prices:
Nelfinavir & Indinavir – Brazil
Cipro – US$1.77 per tab to US$0.95 – US
2001 – Growing recognition of social function of generics
South Africa - Nelson Mandela in the dock for attempting to get cheap drugs for 4.2m AIDS sufferers
Dominican Republic threat to textiles
Brazil - Successful HIV/AIDS programme under threat 50% mortality cut
impact of length and scope of pharmaceutical patenting and amend TRIPS to ensure access